Study on real-world prescription of mirogabalin besilate using the pharmacy claims database

Study on real-world prescription of mirogabalin besilate using the pharmacy claims database - Study on real-world prescription of mirogabalin besilate

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042592

Enrollment

13000

Registered

2020-12-01

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients having prescriptions filled at Japanese insurance pharmacies operating under an agreement with the contract research organization between June 1, 2020 and August 31, 2020 and prescribed mirogabalin besilate

Exclusion criteria

Exclusion criteria: Patients prescribed mirogabalin besilate within 180 days before the first prescription

Design outcomes

Primary

Measure	Time frame
Number of patients prescribed mirogabalin besilate	—

Secondary

Measure	Time frame
1) Starting dose of mirogabalin besilate and changes in prescribed daily dose over time 2) Maintenance dose of mirogabalin besilate 3) Total and mean prescribed doses of mirogabalin besilate 4) Percentage of patients receiving oral analgesics in combination with mirogabalin besilate by co-administration pattern 5) Medication possession ratio (MPR) of mirogabalin besilate 6) Percentage of patients discontinuing mirogabalin besilate therapy	—

Measure

Time frame

1) Starting dose of mirogabalin besilate and changes in prescribed daily dose over time 2) Maintenance dose of mirogabalin besilate 3) Total and mean prescribed doses of mirogabalin besilate 4) Percentage of patients receiving oral analgesics in combination with mirogabalin besilate by co-administration pattern 5) Medication possession ratio (MPR) of mirogabalin besilate 6) Percentage of patients discontinuing mirogabalin besilate therapy

—

Countries

Japan

Contacts

Public ContactMizuka Yokoyama

DAIICHI SANKYO CO., LTD. Medical Science Department

yokoyama.mizuka.j2@daiichisankyo.co.jp03-6225-1053

Outcome results